Search research articles
Contact Us
Filters
Showing results (121-130 of 160) with videos related to
Page
of 16
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2004
Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer
Bradley A Schiff, Andrea B McMurphy, Samar A Jasser, et al.
Lancet (London, England)
|
April 29, 2014
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
Marcia S Brose, Christopher M Nutting, Barbara Jarzab, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2019
Editor's Note: Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in Anaplastic Thyroid Cancer, and the EGFR Inhibitor Gefitinib Inhibits the Growth of Anaplastic Thyroid Cancer
Bradley A Schiff, Andrea B McMurphy, Samar A Jasser, et al.
Journal of the Endocrine Society
|
April 25, 2024
Next-Generation Sequencing in Sporadic Medullary Thyroid Cancer Patients: Mutation Profile and Disease Aggressiveness
Aditya S Shirali, Mimi I Hu, Yi-Ju Chiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 13, 2019
A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers
Razelle Kurzrock, Douglas W Ball, Marianna L Zahurak, et al.
Thyroid : Official Journal of the American Thyroid Association
|
September 28, 2016
Medullary Thyroid Carcinoma Associated with Germline RET<sup>K666N</sup> Mutation
Jian Yu Xu, Elizabeth G Grubbs, Steven G Waguespack, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 28, 2015
A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer
Martin Schlumberger, Barbara Jarzab, Maria E Cabanillas, et al.
The Journal of Clinical Endocrinology and Metabolism
|
September 16, 2017
Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma
Gilbert J Cote, Caitlin Evers, Mimi I Hu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 7, 2021
Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer
Lori J Wirth, Marcia S Brose, Eric J Sherman, et al.
Journal of Cancer Research and Clinical Oncology
|
July 17, 2019
Genetic profiling as a clinical tool in advanced parathyroid carcinoma
Merve Kutahyalioglu, Ha T Nguyen, Lily Kwatampora, et al.
Page
of 16
Search research articles
Search
Showing results (121-130 of 160) with videos related to
Sort By:
Page
of 16
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2004
Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer
Bradley A Schiff, Andrea B McMurphy, Samar A Jasser, et al.
Lancet (London, England)
|
April 29, 2014
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
Marcia S Brose, Christopher M Nutting, Barbara Jarzab, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2019
Editor's Note: Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in Anaplastic Thyroid Cancer, and the EGFR Inhibitor Gefitinib Inhibits the Growth of Anaplastic Thyroid Cancer
Bradley A Schiff, Andrea B McMurphy, Samar A Jasser, et al.
Journal of the Endocrine Society
|
April 25, 2024
Next-Generation Sequencing in Sporadic Medullary Thyroid Cancer Patients: Mutation Profile and Disease Aggressiveness
Aditya S Shirali, Mimi I Hu, Yi-Ju Chiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 13, 2019
A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers
Razelle Kurzrock, Douglas W Ball, Marianna L Zahurak, et al.
Thyroid : Official Journal of the American Thyroid Association
|
September 28, 2016
Medullary Thyroid Carcinoma Associated with Germline RET<sup>K666N</sup> Mutation
Jian Yu Xu, Elizabeth G Grubbs, Steven G Waguespack, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 28, 2015
A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer
Martin Schlumberger, Barbara Jarzab, Maria E Cabanillas, et al.
The Journal of Clinical Endocrinology and Metabolism
|
September 16, 2017
Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma
Gilbert J Cote, Caitlin Evers, Mimi I Hu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 7, 2021
Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer
Lori J Wirth, Marcia S Brose, Eric J Sherman, et al.
Journal of Cancer Research and Clinical Oncology
|
July 17, 2019
Genetic profiling as a clinical tool in advanced parathyroid carcinoma
Merve Kutahyalioglu, Ha T Nguyen, Lily Kwatampora, et al.
Page
of 16